NF-κB activation as a pathological mechanism of septic shock and inflammation | American Journal of Physiology-Lung Cellular and Molecular Physiology
Efficacy and safety of leflunomide versus cyclophosphamide for initial-onset Takayasu arteritis: a prospective cohort study - Sun Ying, Cui Xiaomeng, Dai Xiaomin, Lin Jiang, Lv Peng, Ma Lili, Chen Rongyi, Ji Zongfei,
Individualization of leflunomide dosing in rheumatoid arthritis patients | Personalized Medicine
Schematic representation of leflunomide mechanism of action. It... | Download Scientific Diagram
Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review - ScienceDirect
Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review - ScienceDirect
What Is Leflunomide, Cas No 75706-12-6 Guide - ECHEMI
The role of Chinese herbal medicine in the management of adverse drug reactions of leflunomide in treating rheumatoid arthritis - ScienceDirect
Leflunomide triggers ER stress and UPR in HepG2 cells. (A, B) Total... | Download Scientific Diagram
Leflunomide | C12H9F3N2O2 - PubChem
Current immunotherapy in rheumatoid arthritis | Immunotherapy
Molecules | Free Full-Text | The Mitochondria-Independent Cytotoxic Effect of Leflunomide on RPMI-8226 Multiple Myeloma Cell Line
Leflunomide abrogates neuroinflammatory changes in a rat model of Alzheimer's disease: the role of TNF-α/NF-κB/IL-1β axis inhibition | SpringerLink
Effect of leflunomide (2.5, 5 or10 mg/kg) on hepatic immunostaining for... | Download Scientific Diagram
Frontiers | Pathomechanisms of bone loss in rheumatoid arthritis
Leflunomide–hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial - The Lancet Rheumatology
Inhibiting NF-κB activation by small molecules as a therapeutic strategy. - Abstract - Europe PMC
The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function | Arthritis Research & Therapy | Full Text
Chemical structure of leflunomide and its active metabolite A77 1726. | Download Scientific Diagram
Cancers | Free Full-Text | Targeting NF-κB Signaling for Multiple Myeloma
IJMS | Free Full-Text | Effects of Biological Therapies on Molecular Features of Rheumatoid Arthritis
HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis | Nature Communications
Nuclear transcription factor-κB as a target for cancer drug development | Leukemia
Chemical structures of leflunomide and its metabolite A77 1726. | Download Scientific Diagram
Frontiers | LncRNAs and Rheumatoid Arthritis: From Identifying Mechanisms to Clinical Investigation
The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells | Leukemia
Nuclear Factor κB Signaling in Atherogenesis | Arteriosclerosis, Thrombosis, and Vascular Biology
